LEI: 213800FLQUB9J289RU66
19 July 2022
BATM Advanced Communications Limited
("BATM" or "the Group")
Appointment of CEO of ADOR Diagnostics
Bioscience expert appointed to lead advanced molecular diagnostics associate company
BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, is pleased to announce the appointment of Dr. Eran Zahavy as CEO of ADOR Diagnostics ("ADOR"), the Group's associate company that is developing the NATlab rapid molecular diagnostics platform.
Dr. Eran Zahavy has more than 20 years' experience in leading positions in government and private bio-science organisations. This includes roles such as R&D manager for biological pathogens diagnostics and Head of Innovation at the Israel Institute for Biological Research ("IIBR"). During the pandemic, at IIBR he oversaw the development of the BriLife COVID-19 vaccine in collaboration with US-based NRx Pharmaceuticals. Other roles have included serving as CTO at Hutchison Kinrot, the operator of a technology incubator in Israel and a seed investor in water and cleantech-related technologies; CTO of TACount, a developer of imaging-based microbiological testing technology; and as scientific advisor to Longliv Ventures, a strategic investor in health-tech start-ups and part of the CK Hutchison Holdings Group.
For the last few years, Dr. Zahavy has served as CTO of the Group's Bio-Medical Division and as Senior Scientific Consultant to ADOR and BATM's Adaltis diagnostics subsidiary. During this time, he has been instrumental in the progress made in the Group's molecular diagnostics activities.
Dr. Zahavy holds a PhD in Chemistry & Biophysics from the Hebrew University and undertook a postdoc at the University of Texas, Austin and the University of California, San Diego. He has more than 40 peer reviewed scientific publications to his name as well as patents.
Dr. Zvi Marom, CEO of BATM, said: "We're pleased to have appointed Eran as CEO of ADOR. He has an impressive track record of bioscience development and has been critical to the fantastic progress that we have made in our Bio-Medical Division in recent years. It is an exciting time for ADOR as we move to the pre-production phase and towards becoming a commercial clinical solution. We look forward to leveraging Eran's experience and expertise for the next stage of development in ADOR."
ADOR is developing the NATlab system, which is a molecular diagnostics platform that uses the isothermal amplification (RCA) process to provide rapid sample-to-answer testing of pathogens. The NATlab instrument tests for multiple pathogens using a single cartridge, with different cartridges being designed for different infectious disease panels, such as meningitis, respiratory diseases, STIs and more. The Group, through ADOR and Adaltis, is also partnering with the Stop TB Partnership to develop a solution for the rapid and comprehensive diagnosis of tuberculosis.
Dr. Eran Zahavy, CEO of ADOR Diagnostics, added: "I am excited to be taking up this role with ADOR. We are paving a new path for the diagnosis of infectious diseases. With a rapid diagnostics solution that can be operational at both the point of care and in labs, we can enable the appropriate and immediate treatment of disease, which is better for patients and for public health authorities."
Enquiries:
| BATM Advanced Communications | |
| Dr Zvi Marom, Chief Executive Officer | +972 9866 2525 |
| Moti Nagar, Chief Financial Officer | |
|
| |
| Luther Pendragon | |
| Harry Chathli, Claire Norbury | +44 20 7618 9100 |
Forward-looking statements
This document contains forward-looking statements. Those statements reflect the current opinions, evaluations and estimations of the Group's management, and are based on the current data regarding the Group's business as is detailed in this document and in the Group's periodical, interim and immediate reports. The Group does not undertake any obligation or make any representation that actual results and events will be in line with those statements, and stresses that they may differ materially from those statements, due to changes in the Group's business, market, competition, demand for the Group's products or services, general economic factors or other factors that can influence the Group's business and results, and due to information and factors that are currently unknown to the Group's management and that, if known, would affect the management's opinions, evaluations or estimations. The Group will report the actual results and events according to its legal, accounting and regulatory obligations, and does not undertake any other obligation to report them or their deviations from the forward-looking statements, or to update any of the forward-looking statements in this document or to report that it is not valid anymore.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
